{"url_path":"/sec/ndra/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-057680-index.html","accession_number":"0001213900-26-057680","cik":"0001681682","ticker":"NDRA","issuer_name":"ENDRA Life Sciences Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1681682/0001213900-26-057680-index.html","primary_entity_key":"0001681682","primary_entity_name":"ENDRA Life Sciences Inc."},"word_count":39,"has_tables":true,"body_markdown":"**Item 5. Other Information**\n\n \n\n**Rule 10b5-1 Trading Plans**\n\n \n\nNone of the Company’s directors or officers\nadopted, modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s\nfiscal quarter ended March 31, 2026."}